News Posts List
A Patient-friendly Summary of the 11th International Kidney Cancer Symposium
12/01/2012
The standard of care for small renal masses has shifted from radical nephrectomy to a strategy to preserve the volume of working kidney as well as the quality of life of the patient. Depending on the size of the tumor and the tissue type (as determined by biopsy), small masses might be watched, or a partial nephrectomy performed to remove the tumor and save as much kidney as possible.
FDA Rejection. EU Withdrawal. Set and Match?
11/30/2012
Merck is testing ridaforolimus in other cancer types including kidney cancer.
Learn About the ASCO Quality Care Symposium
11/30/2012
Conquer Cancer Foundation of ASCO Honors Researchers for Work in Measuring and Improving the Quality of Cancer Care
Lots of Talk, Little Action on Medicare Fraud
11/29/2012
Who are you going to believe, him or your lying eyes? During his re-election campaign, President Obama said that his administration has pursued “fraud in Medicare and Medicaid very aggressively—more aggressively than ever before.” America’s seniors deserve to know the truth behind this misleading assertion.
Podcast from VHL Family Alliance: Conquering Kidney Cancer
11/29/2012
What is the IKCS and why should it matter to patients living with kidney cancer?
FDA will review a drug candidate for kidney cancer
11/29/2012
AVEO Oncology, a Cambridge-based cancer therapeutics company, and its Japanese partner Astellas Pharma Inc. said Wednesday that federal regulators have agreed to review its drug candidate for kidney cancer.
Kidney tumors may be smarter than previously thought
11/23/2012
Scientists have been trying to figure out how different people have kidney tumours with the same histology, or shape, although the genetic changes can vary among individual tumours.
Will the Affordable Care Act make this happen in the USA, too?
11/22/2012
Doctors 'are withholding treatment from dying cancer patients because they think it is futile to continue'
Potential tumor markers of renal cell carcinoma
11/19/2012
α-Enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection
Journal ONCOLOGY Offers Two-Part "Primer" on Targeted Therapies in Solid Tumors
11/18/2012
Targeted therapy has become both the centerpiece of the current era in cancer therapeutics and the foundation of the field's hope for future progress. Although the initial successes of targeted therapies occurred in hematologic malignancies, recent years have seen a string of promising results in a number of solid tumors.
News Feed